Estrella Immunopharma (NASDAQ:ESLA) Earns “Buy” Rating from D. Boral Capital

Estrella Immunopharma (NASDAQ:ESLA)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They presently have a $8.00 price objective on the stock. D. Boral Capital’s price objective suggests a potential upside of 479.71% from the company’s current price.

Several other research firms also recently weighed in on ESLA. Wall Street Zen raised shares of Estrella Immunopharma from a “sell” rating to a “hold” rating in a research report on Saturday, January 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Estrella Immunopharma in a research note on Wednesday, January 28th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Estrella Immunopharma presently has an average rating of “Hold” and an average price target of $8.00.

Estrella Immunopharma Trading Down 3.2%

Estrella Immunopharma stock opened at $1.38 on Monday. Estrella Immunopharma has a 52 week low of $0.73 and a 52 week high of $3.15. The stock has a market cap of $52.12 million, a P/E ratio of -4.06 and a beta of 0.55. The stock has a 50 day moving average of $1.39 and a 200-day moving average of $1.44.

Estrella Immunopharma (NASDAQ:ESLA) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.06.

Institutional Investors Weigh In On Estrella Immunopharma

An institutional investor recently raised its position in Estrella Immunopharma stock. Geode Capital Management LLC increased its holdings in shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) by 8.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 109,808 shares of the company’s stock after acquiring an additional 8,318 shares during the quarter. Geode Capital Management LLC owned approximately 0.29% of Estrella Immunopharma worth $171,000 at the end of the most recent quarter. 0.35% of the stock is currently owned by hedge funds and other institutional investors.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.